RXRX — Recursion Pharmaceuticals, Inc.

Summary of RXRX Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Cash Position: Ended the year with $754 million in cash.
• Operating Expenses: Achieved a 35% reduction in pro forma operating expenses year-over-year, coming in 10% below prior guidance.
• Cash Runway: Extended cash runway into early 2028.
• Partnership Revenue: Cumulative partner inflows exceeded $500 million, with significant contributions from milestones and upfront payments.

2. Strategic Updates and Business Highlights

• Clinical Development: Positive proof of concept for REC-4881 (FAP), with plans for FDA engagement in 2026.
• Partnerships: Achieved fifth milestone with Sanofi, totaling approximately $134 million in milestones and upfront payments.
• Platform Advancements: Continued investment in an end-to-end AI platform, focusing on AI-driven biology, chemistry, and clinical development.
• Portfolio Diversification: Maintained a diversified clinical pipeline with multiple programs targeting unmet medical needs.

3. Forward Guidance and Outlook

• Upcoming Catalysts: Anticipated milestones include initial FDA engagement for REC-481, early safety and pharmacokinetics data for RBM39, and go/no-go decisions for PI3K and ENPP1 programs.
• Operational Focus: Emphasis on disciplined execution and efficiency in operations, aiming to do more with less while advancing the pipeline.

4. Bad News, Challenges, or Points of Concern

• Regulatory Uncertainty: While REC-4881 shows promise, the path to regulatory approval remains uncertain and contingent on FDA discussions.
• Market Competition: The biotech sector is competitive, with the need for Recursion to demonstrate the repeatability and scalability of its platform amidst evolving industry standards.
• Operational Risks: The inherent probabilistic nature of drug discovery poses risks, with a high failure rate in clinical trials.

5. Notable Q&A Insights

• Regulatory Pathway for REC-4881: The company is preparing for initial FDA engagement in 2026, focusing on study design and patient population.
• Cost Optimization: Management clarified that recent reductions in operating expenses stem from efficiency improvements rather than one-off cost cuts.
• Partnership with NVIDIA: The technical collaboration with NVIDIA remains strong despite NVIDIA's divestment from equity investment, with ongoing projects leveraging advanced computing capabilities.
• Clinical Success Metrics: The company highlighted its ability to synthesize significantly fewer compounds than industry standards while achieving faster development timelines, indicating improved efficiency in its drug discovery process.

Overall, Recursion Pharmaceuticals is positioned at a critical juncture with a strong cash position, promising clinical developments, and a focus on leveraging AI in drug discovery, while navigating regulatory challenges and competitive pressures.